CCM
FTH

Catalio Capital Management’s Faeth Therapeutics FTH Stock Holding History

Catalio Capital Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$464K Hold
14,718
– – 0.1% 40
2025
Q4 		$157K Hold
14,718
– – 0.03% 45
2025
Q3 		$139K Hold
14,718
– – 0.03% 38
2025
Q2 		$126K Sell
14,718
-1
-0% -$7 0.03% 40
2025
Q1 		$116K Hold
14,719
– – 0.03% 37
2024
Q4 		$144K Buy
+14,719
New +$148K 0.03% 33

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Catalio Capital Management's FTH Position: Q1 2026 in Review

Catalio Capital Management held its Faeth Therapeutics (FTH) position steady in Q1 2026 at 14,718 shares worth $464K. The position accounts for 0.1% of the portfolio, ranked #40.

Catalio Capital Management first reported a position in FTH in Q4 2024 and has held it in 6 quarters since. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • Catalio Capital Management held 14,718 shares of Faeth Therapeutics worth $464K as of Q1 2026.
  • Catalio Capital Management left its Faeth Therapeutics share count unchanged in Q1 2026.
  • Faeth Therapeutics made up 0.1% of Catalio Capital Management's portfolio in Q1 2026, its #40 holding.
  • Catalio Capital Management first reported a position in Faeth Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.